|
1
|
Chen L, Magliano DJ and Zimmet PZ: The
worldwide epidemiology of type 2 diabetes mellitus-present and
future perspectives. Nat Rev Endocrinol. 8:228–236. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Battiprolu PK, Lopez-Crisosto C, Wang ZV,
Nemchenko A, Lavandero S and Hill JA: Diabetic cardiomyopathy and
metabolic remodeling of the heart. Life Sci. 92:609–615. 2013.
View Article : Google Scholar :
|
|
3
|
Schilling JD and Mann DL: Diabetic
cardiomyopathy: Bench to bedside. Heart Fail Clin. 8:619–631. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuethe F, Sigusch HH, Bornstein SR, Hilbig
K, Kamvissi V and Figulla HR: Apoptosis in patients with dilated
cardiomyopathy and diabetes: A feature of diabetic cardiomyopathy?
Horm Metab Res. 39:672–676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiordaliso F, Li B, Latini R, Sonnenblick
EH, Anversa P, Leri A and Kajstura J: Myocyte death in
streptozotocin-induced diabetes in rats in angiotensin
II-dependent. Lab Invest. 80:513–527. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baraka A and AbdelGawad H: Targeting
apoptosis in the heart of streptozotocin-induced diabetic rats. J
Cardiovasc Pharmacol Ther. 15:175–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Witko-Sarsat V, Friedlander M,
Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers
P and Descamps-Latscha B: Advanced oxidation protein products as a
novel marker of oxidative stress in uremia. Kidney Int.
49:1304–1313. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalousová M, Skrha J and Zima T: Advanced
glycation end-products and advanced oxidation protein products in
patients with diabetes mellitus. Physiol Res. 51:597–604. 2002.
|
|
9
|
Kaneda H, Taguchi J, Ogasawara K, Aizawa T
and Ohno M: Increased level of advanced oxidation protein products
in patients with coronary artery disease. Atherosclerosis.
162:221–225. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atabek ME, Keskin M, Yazici C, Kendirci M,
Hatipoglu N, Koklu E and Kurtoglu S: Protein oxidation in obesity
and insulin resistance. Eur J Pediatr. 165:753–756. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tabak O, Gelisgen R, Erman H, Erdenen F,
Muderrisoglu C, Aral H and Uzun H: Oxidative lipid, protein and DNA
damage as oxidative stress markers in vascular complications of
diabetes mellitus. Clin Invest Med. 34:E163–E171. 2011.PubMed/NCBI
|
|
12
|
Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N,
Nagai R, Lu X, Chen BH, Shan YX and Tian JW: Advanced oxidation
protein products activate vascular endothelial cells via a
RAGE-mediated signaling pathway. Antioxid Redox Signal.
10:1699–1712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou LL, Hou FF, Wang GB, Yang F, Xie D,
Wang YP and Tian JW: Accumulation of advanced oxidation protein
products induces podocyte apoptosis and deletion through
NADPH-dependent mechanisms. Kidney Int. 76:1148–1160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gaspari T, Liu H, Welungoda I, Hu Y,
Widdop RE, Knudsen LB, Simpson RW and Dear AE: A GLP-1 receptor
agonist liraglutide inhibits endothelial cell dysfunction and
vascular adhesion molecule expression in an ApoE-/-mouse model.
Diab Vasc Dis Res. 8:117–124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lønborg J, Vejlstrup N, Kelbæk H, Bøtker
HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K,
Clemmensen P, et al: Exenatide reduces reperfusion injury in
patients with ST-segment elevation myocardial infarction. Eur Heart
J. 33:1491–1499. 2012. View Article : Google Scholar
|
|
16
|
Kieffer TJ and Habener JF: The
glucagon-like peptides. Endocr Rev. 20:876–913. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomas E and Habener JF: Insulin-like
actions of glucagon-like peptide-1: A dual receptor hypothesis.
Trends Endocrinol Metab. 21:59–67. 2010. View Article : Google Scholar
|
|
18
|
Liu Q, Anderson C, Broyde A, Polizzi C,
Fernandez R, Baron A and Parkes DG: Glucagon-like peptide-1 and the
exenatide analogue AC3174 improve cardiac function, cardiac
remodeling, and survival in rats with chronic heart failure.
Cardiovasc Diabetol. 9:762010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie Y, Wang SX, Sha WW, Zhou X, Wang WL,
Han LP, Li DQ and Yu DM: Effects and mechanism of glucagon-like
peptide-1 on injury of rats cardiomyocytes induced by
hypoxia-reoxygenation. Chin Med J (Engl). 121:2134–2138. 2008.
|
|
20
|
Zhan Y, Sun HL, Chen H, Zhang H, Sun J,
Zhang Z and Cai DH: Glucagon-like peptide-1 (GLP-1) protects
vascular endothelial cells against advanced glycation end products
(AGEs)-induced apoptosis. Med Sci Monit. 18:BR286–BR291. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Newman RA, Hacker MP and Krakoff IH:
Amelioration of adriamycin and daunorubicin myocardial toxicity by
adenosine. Cancer Res. 41:3483–3488. 1981.PubMed/NCBI
|
|
22
|
Zhou LL, Cao W, Xie C, Tian J, Zhou Z,
Zhou Q, Zhu P, Li A, Liu Y, Miyata T, et al: The receptor of
advanced glycation end products plays a central role in advanced
oxidation protein products-induced podocyte apoptosis. Kidney Int.
82:759–770. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ravassa S, Zudaire A and Díez J: GLP-1 and
cardioprotection: From bench to bedside. Cardiovasc Res.
94:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie F, Sun S, Xu A, Zheng S, Xue M, Wu P,
Zeng JH and Bai L: Advanced oxidation protein products induce
intestine epithelial cell death through a redox-dependent, c-jun
N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated
pathway. Cell Death Dis. 5:e10062014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong ZM, Bai L and Chen JT: Advanced
oxidation protein products inhibit proliferation and
differentiation of rat osteoblast-like cells via NF-kappaB pathway.
Cell Physiol Biochem. 24:105–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valente AJ, Yoshida T, Clark RA,
Delafontaine P, Siebenlist U and Chandrasekar B: Advanced oxidation
protein products induce cardiomyocyte death via
Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling. Free Radic
Biol Med. 60:125–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cai L, Wang Y, Zhou G, Chen T, Song Y, Li
X and Kang YJ: Attenuation by metallothionein of early cardiac cell
death via suppression of mitochondrial oxidative stress results in
a prevention of diabetic cardiomyopathy. J Am Coll Cardiol.
48:1688–1697. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuethe F, Sigusch HH, Bornstein SR, Hilbig
K, Kamvissi V and Figulla HR: Apoptosis in patients with dilated
cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy?
Horm Metab Res. 39:672–676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piwowar A, Knapik-Kordecka M and Warwas M:
Markers of oxidative protein damage in plasma and urine of type 2
diabetic patients. Br J Biomed Sci. 66:194–199. 2009.
|
|
30
|
Piwowar A, Knapik-Kordecka M and Warwas M:
AOPP and its relations with selected markers of
oxidative/antioxidative system in type 2 diabetes mellitus.
Diabetes Res Clin Pract. 77:188–192. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Narula J, Arbustini E, Chandrashekhar Y
and Schwaiger M: Apoptosis and the systolic dysfunction in
congestive heart failure. Story of apoptosis interruptus and zombie
myocytes. Cardiol Clin. 19:113–126. 2001. View Article : Google Scholar
|
|
32
|
Puddu A, Storace D, Durante A, Odetti P
and Viviani GL: Glucagon-like peptide-1 counteracts the detrimental
effects of advanced glycation end-products in the pancreatic beta
cell line HIT-T 15. Biochem Biophys Res Commun. 398:462–466. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marzioni M, Alpini G, Saccomanno S,
Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L
and Benedetti A: Exendin-4, a glucagon-like peptide 1 receptor
agonist, protects cholangiocytes from apoptosis. Gut. 58:990–997.
2009. View Article : Google Scholar :
|
|
34
|
Harkavyi A and Whitton PS: Glucagon-like
peptide 1 receptor stimulation as a means of neuroprotection. Br J
Pharmacol. 159:495–501. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ravassa S, Zudaire A, Carr RD and Diez J:
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J
Physiol Heart Circ Physiol. 300:H1361–H1372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS,
Drucker DJ and Husain M: Cardioprotective and vasodilatory actions
of glucagon-like peptide 1 receptor are mediated through both
glucagon-like peptide 1 receptor-dependent and -independent
pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bullock BP, Heller RS and Habener JF:
Tissue distribution of messenger ribonucleic acid encoding the rat
glucagon-like peptide-1 receptor. Endocrinology. 137:2968–2978.
1996.PubMed/NCBI
|
|
38
|
Younce CW, Burmeister MA and Ayala JE:
Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis
via inhibition of endoplasmic reticulum stress and activation of
SERCA2a. Am J Physiol Cell Physiol. 304:C508–C518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Timmers L, Henriques JP, de Kleijn DP,
Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek
JJ, Doevendans PA, et al: Exenatide reduces infarct size and
improves cardiac function in a porcine model of ischemia and
reperfusion injury. J Am Coll Cardiol. 53:501–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ban K, Kim KH, Cho CK, Sauvé M, Diamandis
EP, Backx PH, Drucker DJ and Husain M: Glucagon-like peptide
(GLP)-1 (9-36) amide-mediated cytoprotection is blocked by exendin
(9-39) yet does not require the known GLP-1 receptor.
Endocrinology. 151:1520–1531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huisamen B, Genis A, Marais E and Lochner
A: Pre-treatment with a DPP-4 inhibitor is infarct sparing in
hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther.
25:13–20. 2011. View Article : Google Scholar
|
|
42
|
Yao R and Cooper GM: Requirement for
phosphati-dylinositol-3 kinase in the prevention of apoptosis by
nerve growth factor. Science. 267:2003–2006. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mullonkal CJ and Toledo-Pereyra LH: Akt in
ischemia and reperfusion. J Invest Surg. 20:195–203. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shao S, Nie M, Chen C, Chen X, Zhang M,
Yuan G, Yu X and Yang Y: Protective action of liraglutide in beta
cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway. J Cell
Biochem. 115:1166–1175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang G, Zhang P, Ye L, Lu K, Wang Y, Duan
Q, Zheng A, Qin S and Zhang D: Protective effects of sitagliptin on
myocardial injury and cardiac function in an ischemia/reperfusion
rat model. Eur J Pharmacol. 718:105–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chipuk JE and Green DR: How do BCL-2
proteins induce mitochondrial outer membrane permeabilization?
Trends Cell Biol. 18:157–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dejean LM, Ryu SY, Martinez-Caballero S,
Teijido O, Peixoto PM and Kinnally KW: MAC and Bcl-2 family
proteins conspire in a deadly plot. Biochim Biophys Acta.
1797:1231–1238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cunha DA, Ladrière L, Ortis F,
Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL and
Cnop M: Glucagon-like peptide-1 agonists protect pancreatic
beta-cells from lipotoxic endoplasmic reticulum stress through
upregulation of BiP and JunB. Diabetes. 58:2851–2862. 2009.
View Article : Google Scholar : PubMed/NCBI
|
